**12. QoL differences in transplant-ineligible myeloma patients treated with different drug combinations**

The phase 3 VISTA study (ClinicalTrials.gov NCT00111319) in transplant-ineligible myeloma patients demonstrated superior efficacy with bortezomib-melphalan-prednisone (VMP; nine 6-wk cycles) vs. melphalan-prednisone (MP) but also increased toxicity. HRQoL was evaluated using the EORTC-QLQ-C30 questionnaire. Results demonstrated clinically meaningful, transitory HRQoL decrements with VMP and relatively lower HRQoL vs. MP during early treatment cycles, associated with the expected additional toxicities. However, HRQoL is not compromised in the long term, recovering by the end-of-treatment visit to be comparable vs. MP. Analyses by bortezomib dose intensity indicated better HRQoL in patients receiving lower dose intensity [29].
